Krista Qualmann on Genetic Counseling and Testing for Patients with Cancer

Video

Krista Qualmann discusses hereditary cancer syndromes.

Krista Qualmann, MS, CGC, Memorial Hermann Mischer Neuroscience Institute at the Texas Medical Center and UTHealth, discusses hereditary cancer syndromes.

About 5% to 10% of cancers are caused by single-gene disorders. These hereditary cancer syndromes are most well-known for causing cancers such as breast cancer, ovarian cancer and endometrial cancer. They can also have a hand in colon cancer, brain tumors and melanoma.

Recent Videos
image of a woman in front of a blue background with a navy top
woman with a white top sitting in front of a green wall
a man wearing a suit and tie in front of a green screen with the ONN logo
a woman sitting in front of a green wall with a white top and glasses
Related Content
yellow background with a white outline indicating a brain

Dordaviprone Seeks FDA Approval for Recurrent H3K27M+ Diffuse Glioma

Chris Ryan
January 5th 2025
Article

A new drug application has been submitted to the FDA for dordaviprone to treat recurrent H3K27M-mutant diffuse glioma.

Improving The Rate Of Accurate Inflammatory Breast Cancer Diagnoses

Improving The Rate Of Accurate Inflammatory Breast Cancer Diagnoses

Lindsay Fischer
October 2nd 2023
Podcast

Ryan Tamargo, NP, AONCP, discusses the launch of an online inflammatory breast cancer scoring system tool.

gynecologic cancer

Lunresertib/Camonsertib Combo Yields Promising Response in Gynecologic Cancers

Chris Ryan
December 26th 2024
Article

Lunresertib plus camonsertib showed promising efficacy in advanced endometrial and platinum-resistant ovarian cancers, with ORRs of 25.9% and 37.5%, respectively.

The Vitals

Jacki Garcia and Kristin Hendrickson on Navigating Patients Through Phase 0 Trials

Lindsay Fischer
July 15th 2023
Podcast

Jacki Garcia, RN, BSN, CNRN; and Kristin Hendrickson, BA, RN, discuss phase 0 trials and how they can help expedite the research process for brain cancer therapies.

breast cancer

Ribociclib Combo May Provide Benefit to Certain Breast Cancer Subtypes

Darlene Dobkowski, MA
December 23rd 2024
Article

Ribociclib plus endocrine therapy shows PFS benefit in luminal B/HER2E breast cancer subtypes compared to chemotherapy, especially with low immune-related gene expression.

PARP inhibitor

Neoadjuvant Niraparib/Dostarlimab Combo May Yield pCRs in BRCS+, ER+/HER2- Breast Cancer

Ariana Pelosci
December 19th 2024
Article

Additional exploration may help fully realize the impact of combining immunologic approaches with PARP inhibition, says one expert.